Update and optimization of active surveillance in prostate cancer in 2021

Autor: L.M. Esteban Escaño, B. Pastor Navarro, J. Rubio-Briones, A. Borque Fernando
Rok vydání: 2021
Předmět:
Zdroj: Actas Urológicas Españolas (English Edition). 45:1-7
ISSN: 2173-5786
Popis: Introduction and objectives Within the paradigm shift of the last decade in the management of prostate cancer (PCa), perhaps the most relevant event has been the emergence of active surveillance (AS) as a mandatory strategy in low-risk disease. We carry out a critical review of the clinical, pathological and radiological improvements that allow optimizing AS in 2021. Material and methods Critical narrative review of the literature on improvement issues and controversial aspects of AS. Results Adequate use of traditional criteria, optimized by enhanced biopsy and calculation of the prostate volume technique thanks to multiparametric magnetic resonance imaging (mpMRI) allow a better selection of patients for AS. This management should not be limited to patients under 60 years of age, and patients with intermediate-risk PCa should be carefully selected to be included. Biopsies are still required in the follow-up, which can be personalized according to risk patterns. The pathologist must identify the cribriform or intraductal histology on biopsies in order to exclude these patients from AS, in the same way as with patients with alterations in DNA repair genes. Conclusions Controversial indications such as the inclusion of patients from intermediate-risk groups, or the transition to active treatment due to exclusive progression in tumor volume, should be further optimized. It is possible that the future competition of tissue biomarkers, the refinement of objective parameters of mpMRI and the validation of PSA kinetics calculators may sub-stratify risk groups.
Databáze: OpenAIRE
Externí odkaz: